About this trial
Chronic Obstructive Pulmonary Disease (COPD), , secondary to smoking, is a major public health issue with very high direct and indirect costs. The impact on the health system of undiagnosed patients, up to 70% of patients, is increasingly documented. However, systematic spirometry screening remains controversial among smokers in the absence of data to link the detection of new patients with improved management and clinical events and health goals. More generally, there is little data on the evolution of patients in real life once they have entered the care system.
The premise is that with systematic screening in general medicine, it is possible to identify the evolution of newly diagnosed COPD patients, to distinguish the different possible evolutions according to the initial phenotype and the management.
Eligibility criteria
Qualifiers
Age> 35 years
Smoking > 20 PA
Active smoking (cessation < 1 month)
Signature of consent to participate in Phase I of the study
Disqualifiers
Known COPD
Cancer being treated
No affiliation to the social security or other social protection scheme
Pregnant or lactating woman
Trial design
Treatments tested in this trial
- Exhaustive exploration